(concentrated solution for infusion) 4 mg/5 ml
Active Ingredient: Zoledronic acid
Treatment of tumour-induced hypercalcaemia (TIH). Zolapor slows progression of skeletal conditions in adults when used in conjunction with antineoplastic therapy in patients with advanced carcinoma of the breast, prostate, lung and myeloma.
Market by Pharmacentrix (Pty) Ltd for Activo (Pty) Ltd
Active Ingredient: Exemestane
Used for the treatment, control, prevention, and improvement of breast cancer in postmenopausal women.
Marketed by Pharmacentrix for HCR Equity Pharmaceuticals PTY Ltd
Package insert coming soon.
50 mg/150 mg Tablets
Active Ingredient: Bicalutamide
Treatment of advanced prostate cancer in combination with luteinising hormone releasing hormone (LHRH) analogue therapy or surgical castration.
150 mg /500 mg Tablets
Active Ingredient: Capecitabine
Indicated in patients with Dukes C colon cancer, as an adjuvant treatment post-surgery.
Metastatic colorectal cancer
Indicated in patients with metastatic colorectal adenocarcinoma. The benefit relates to time to progression, while overall survival was not influenced.
Indicated for the treatment of patients with advanced gastric adenocarcinoma, as first line treatment, in combination with other anti-chemotherapeutic treatment. The benefit relates to time to progression, while overall survival was not influenced.
Metastatic breast cancer (combination therapy)
In combination with docetaxel, Capecitabine Specpharm is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy which should have included an anthracycline.
Metastatic breast cancer (monotherapy)
Indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy treatment or when further anthracycline treatment is not indicated.
Market by Pharmacentrix (Pty) Ltd for Specpharm (Pty) Ltd